These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2145896)

  • 1. Cytochrome P450dbl phenotypes in malignant and benign breast disease.
    Pontin JE; Hamed H; Fentiman IS; Idle JR
    Eur J Cancer; 1990; 26(7):790-2. PubMed ID: 2145896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine hydroxylation in a Polish population.
    Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
    Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
    Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
    J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
    Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
    Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
    Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
    Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of debrisoquine phenotype.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1991 Mar; 337(8741):623. PubMed ID: 1671985
    [No Abstract]   [Full Text] [Related]  

  • 10. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 11. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility.
    Buchert ET; Woosley RL; Swain SM; Oliver SJ; Coughlin SS; Pickle L; Trock B; Riegel AT
    Pharmacogenetics; 1993 Dec; 3(6):322-7. PubMed ID: 8148873
    [No Abstract]   [Full Text] [Related]  

  • 16. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
    Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
    Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is debrisoquine hydroxylation modified during acute viral hepatitis?
    Joanne C; Paintaud G; Bresson-Hadni S; Magnette J; Becker MC; Miguet JP; Bechtel PR
    Fundam Clin Pharmacol; 1994; 8(1):76-9. PubMed ID: 8181799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine hydroxylation in Parkinson's disease.
    Steiger MJ; Lledo P; Quinn NP; Marsden CD; Turner P; Jenner PG
    Acta Neurol Scand; 1992 Aug; 86(2):159-64. PubMed ID: 1414226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
    Nikolov IG; Chernozemsky IN; Idle JR
    IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.